We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of Single- and Five-fraction Regimens of Stereotactic Body Radiation Therapy for Peripheral Early-stage Non-small-cell Lung Cancer: A Two-institution Propensity-matched Analysis.
- Authors
Cummings, Michael A.; Sung Jun Ma; Hermann, Gregory; Serra, Lucas; Syed, Yusef; Malhotra, Harish K.; Yuhchyau Chen; Milano, Michael T.; Gomez-Suescun, Jorge A.; Singh, Deepinder P.; Singh, Anurag K.; Ma, Sung Jun; Chen, Yuhchyau
- Abstract
<bold>Purpose: </bold>To evaluate differences in local control (LC), disease-specific (DC), and overall survival (OS) of patients with early-stage non-small-cell lung cancer (NSCLC) treated with single- (SF) versus 5-fraction (FF) stereotactic body radiation therapy (SBRT) at 2 institutions.<bold>Patients and Methods: </bold>Peripheral early-stage NSCLC cases treated with a median dose of 30 Gy in SF or a median dose of 50 Gy in FF were included per institutional practice. Kaplan-Meier and Cox models were used to assess survival. A matched-pair analysis was performed to account for imbalances. Toxicities including Common Terminology Criteria for Adverse Events (CTCAE) grade 3 pneumonitis, chest wall pain requiring long-acting narcotics, and hospitalization for respiratory events 6 months posttreatment were recorded.<bold>Results: </bold>A total of 163 lesions were treated between 2007 and 2015; 65 received SF SBRT and 98 received FF SBRT. Most tumors were T1 (n = 92) and T2 (n = 34) lesions and had adenocarcinoma (n = 77) and squamous cell carcinoma (n = 46) histologies, respectively. In the matched cohort, there were no differences in OS, LC, DC, or progression-free survival between the groups. LC and OS at 1 year in the matched cohort was 95% and 88%, and 87% and 84% in the SF and FF cohorts, respectively. There was 1 grade 3 pneumonitis in the FF group, and 9 total hospitalizations post-SBRT, 3 (5%) in the SF group and 6 (6%) in the FF group.<bold>Conclusions: </bold>No statistically significant differences were seen in LC or DC following SF or FF SBRT in this matched cohort of peripheral lesions. No grade 4 or higher toxicities were reported.
- Publication
Clinical Lung Cancer, 2018, Vol 19, Issue 6, p511
- ISSN
1525-7304
- Publication type
journal article
- DOI
10.1016/j.cllc.2018.07.006